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Introduction
Treatment of arterial stenosis, the atherosclerotic narrowing of arteries, can be successfully carried out using balloon dilatation, also termed angioplasty. However, long-term success of coronary angioplasty remains limited by clinically significant restenosis (renarrowing of treated vessels) in around 30% of patients. 1 The routine use of stents in suitable cases appears to improve patency of arteries in about 10-20% of patients, but has not provided a long-term solution for all lesions in clinical practice. A significant proportion of patients still return with complex in-stent restenosis. Novel delivery systems and therapies used at the time of stent implantation might improve the outlook for these patients.
Porcine models suggest that restenosis after both balloon angioplasty and stent implantation results from smooth muscle cell proliferation, migration and enhanced matrix formation. 2 Although this cannot be directly extrapolated to the pathology of human angioplasty, limited analyses of atherectomy and post-mortem specimens agree that smooth muscle cell proliferation plays at least some part in renarrowing. 3 Smooth muscle cells leave the contractile quiescent state and proliferate by progressing through the cell cycle, with the highest activity 7 days after injury; then matrix formation occurs from 1 week onwards. 4, 5 Transfecting adventitial cells with the gene for an agent that reduces the rate of proliferation may influence neointima volume. Adenovirus vector-mediated delivery of the herpes simplex virus thymidine kinase (HSVtk) gene to arterial tissue reduces neointima after intravenous application of the nucleoside analog ganciclovir. 4 However, resultant cell death and cell lysis leads to cellular protein release and inflammation, which may have modified the response, so that an even greater therapeutic effect might be expected if no cell death had been initiated. 6 Smooth muscle cell proliferation occurs by activation of a cascade of molecules through signal transduction and cell cycle regulation. 6, 7 Strategies aiming to slow or halt cell division without causing cell damage, such as cell cycle inhibitors or a double-stranded DNA decoy with affinity for the binding site of the transcription factor E2F, may thus be preferable. [8] [9] [10] [11] Cecropins are peptides primarily responsible for the antibacterial activity in some insects, including the silk worm; they have also been isolated from porcine small intestine. 12 As a part of the humoral immune system, cecropins are secreted in the hemolymph of different insects and in the small intestine in the pig. 12, 13 Cecropins and their immature forms, pre-pro-cecropins, are cytostatic to mammalian cells at relevant concentrations.
14 Gene therapy involving the delivery of the gene for such a selective cytostatic peptide could reduce proliferation. [15] [16] [17] In addition, cecropins can be secreted by cells; thus, there is potential for a bystander effect, as secreted protein might act on neighboring nontransfected cells.
There is now considerable evidence that local perivascular delivery may have an effect on events in the neointima. [18] [19] [20] Adventitial irritation results in focal intimal thickening, and markers applied to the adventitia can be visualized in intima. It is hypothesized that cells originating from the adventitial layer migrate and contribute to neointimal formation. 21 Adventitial delivery is a novel form of delivery with the potential for creating a local depot of active agent. [22] [23] [24] In this article, the effect of locally delivering the gene for the immature form of cecropin A, one member of this family of peptides, pre-pro-cecropin A, into and around injured arteries using a novel needle injection catheter was investigated.
Results
In vitro studies Forty-eight hours after transfection of smooth muscle cells with a vector containing the gene for green fluorescent protein (GFP), transfection efficiency, assessed by counting GFP-expressing cells at fluorescence microscopy, was approximately 5% (data not shown). At this time-point, expression of pre-pro-cecropin A was detected by RT-PCR in transfected smooth muscle cells transfected with the pre-pro-cecropin A expression plasmid pTRACER-CA (Figure 1 ). After splitting, cell proliferation was reduced in cultures of pre-pro-cecropin A (pTRACER-CA)-transfected smooth muscle cells compared with basic vector pTRACER-SV40-transfected cells. Using fluorescence microscopy, daughter cells demonstrating weak fluorescent staining could clearly be visualized in all wells in control experiments, whereas none were identified in wells containing pre-pro-cecropin A- In time-course experiments, pre-pro-cecropin A-transfected cells were growth inhibited in comparison with pTRACER-SV40-transfected cells (Figure 3 ). After selection for Zeocin-resistant cells, this inhibition of proliferation was increased.
Transgene expression in a porcine restenosis model Plasmids were delivered to the femoral arteries of pigs during balloon angioplasty. Experimental animals tolerated both the balloon angioplasty procedures and local drug delivery with the needle injection catheter ( Figure  4a) , with good recovery and no adverse effects on peripheral anatomy over the time-points studied in any pig (Figure 4b ).
Transferred plasmid DNA was detected with a sensitivity limit of 10 −7 fmol of plasmid against a background of 0.1 g chromosomal DNA, equivalent to 60 plasmid molecules against an estimated background of chromosomal DNA of 15 000 individual cells. 25 Retention of prepro-cecropin A-carrying expression plasmids was demonstrated at both 8 and 21 days by amplification by PCR in the treated arteries ( Figure 5 ). No plasmid DNA was detected in any of the removed organs at either timepoint ( Figure 5 ). Plasmid DNA was not found in untreated arteries or in skeletal muscle taken from the vicinity of the treated arterial segment.
Blood samples taken shortly after local gene therapy indicated that there was no plasmid contamination of blood detectable by PCR, in contrast to pigs receiving 30 g of DNA systemically ( Figure 6 ). The detection limit was estimated using plasmid added in vitro to blood samples in a concentration ranging from 1 ng/l to 1 fg/l serum. The gene for ␤-galactosidase was detectable by PCR as low as 10 −6 fmol. In 3 l of pig serum this would represent a detection limit of 0.1% of the total 30 g plasmid applied with the needle injection catheter if contamination occurred.
The transfection efficiency was evaluated by in situ ␤-galactosidase staining performed on tissue sections of arteries treated with the control plasmid carrying the ␤-galactosidase gene. Single positive cells in neointimal, medial and adventitial arterial wall layers were demonstrated, with the highest cell count at 8 days (Figure 7) . At 8 days, the mean transfection efficiency in both layers was one stained cell in 1210 (±146) cells. No background staining was observed.
Both pre-pro-cecropin A-specific and neomycin resistance gene transcripts could be detected in treated arteries at 8 and 21 days after treatment (Figure 8 ).
Morphometric analysis was carried out on sections from balloon-injured iliac arteries from six animals treated with therapeutic gene. The opposite iliac arteries were treated with the reporter gene; uninjured normal iliac arteries from three pigs were used as further controls. Sections were evaluated morphologically after elastic trichrome staining (Figure 9a-c) . Dilated arteries treated with the pre-pro-cecropin A-plasmid demonstrated a significant reduction in neointimal area (0.05 ± 0.02 mm 
f). Comparable cell numbers were seeded; the confluency of the cell layer is reduced by transfection with pre-pro-cecropin A encoding pTRACER-CA vector (d, e). Transfected cells were detected in both cultures by GFP-expression (green staining) demonstrating similar transfection efficiencies (b, e). Original magnification 400 ×. Fixed cells were stained with DAPI (blue) and photographed (c, f). Daughter cells were only found in pTRACER-SV40 control-transfected cells (c). Original magnification 1055 ×.
to indicate the presence of the proliferation antigen Ki67. There was significantly reduced expression of Ki67 in the arterial media of pre-pro-cecropin A-transfected vessels (2.1 ± 1.4 cells per segment), compared with control injured arteries which had not undergone therapeutic gene delivery (15.5 ± 12.1 cells per segment, P Ͻ 0.01) (Figure 10 ), indicating an effect on proliferation following gene therapy.
Discussion
A catheter-based rather than surgical gene delivery system 7 was selected for the study, with its potential for clinical use in preventing restenosis. This version of the needle injection catheter could also be used in human peripheral arteries and in proximal coronary arteries.
The needle injection catheter is a form of active deliv-
Figure 3 Proliferation assays of smooth muscle cells after transfection with pre-pro-cecropin A encoding pTRACER-CA. Primary porcine smooth muscle cells were transfected with the basic vector pTRACER-SV40 or the SV40 promoter-driven pre-pro-cecropin A containing pTRACER-CA plasmid. Results from triplicate wells from two independent experiments are shown. After 48 h, cells were split 1:3 and grown for 72 h (a) as before or (b) with the addition of 500 g/ml Zeocin. Cells with no selection were counted at 3, 5 or 7 days after passaging and cells treated with Zeocin were counted 5, 7 or 10 days after passaging. After splitting the transfected cells, those transfected with pTRACER-CA (̆, ) showed a reduced growth rate (a) in comparison with cells in control experiments with pTRACER-SV40 (v). The effect is increased by Zeocin selection (b), leading to a relatively higher amount of transfected cells in the surviving population.
ery with high efficiency. Passive delivery of gene therapy, for example with a double balloon catheter, results in minimal deposition in deeper arterial wall layers, local persistence of only hours and distal waste, with potential systemic toxicity. 26 Local delivery with pressure-driven catheters such as the porous balloon may cause additional arterial trauma by forcing jets of fluid into vascular tissue. 27 In contrast, the ultra thin needles of the injection catheter cause only minute injuries which heal almost without scarring. 22 By delivering to perivascular tissue, the needle injection catheter has several further advantages over previously described catheters. The adventitia may itself be a relevant site for the initiation of cell migration into the neointima after arterial injury. [20] [21] [22] Perivascular tissue appears to act as a depot, and adventially delivered substances can be observed in all arterial layers, including inner layers, for up to 21 days with the needle injection catheter. 23 Similarly, our studies demonstrated the presence of delivered gene and its mRNA within the arterial wall up to 21 days after delivery. The dosage of 30 g DNA was less than a tenth of that used in comparable experiments where the local drug delivery devices were modified balloon catheters. 28, 29 With adventitial gene delivery, it was confirmed that there was little systemic loss. All organs explanted and blood samples taken shortly after transfection using sensitive detection methods were free of plasmids. Other delivery catheters demonstrate more distal loss. 26 Perfusion catheter gene delivery results in detection of transgenes in liver in a significant proportion of experimental animals. 30 This study demonstrates that perivascular delivery of a reporter gene using the needle injection catheter is feasible, with positively stained cells detected in adventitia, media and neointima. Transfection efficiency was approximately one in 1000 at 8 days. Although the study was not able to analyze the production of gene-related protein, as no antibody against cecropin A is yet available, studies on protein production from other therapeutic genes show similar transfection efficiencies in this model. 24 We used reverse transcription PCR to confirm specific mRNA from transferred gene in parallel with the observed therapeutic effect.
The absolute transfection efficiency achieved through the use of the needle injection catheter may not appear better than those obtained with other methods of delivering gene therapy, although the depot effect, up to 3 weeks after delivery, is notable. In addition, we confined ourselves to relatively low DNA dosages, knowing from non-gene therapy work that most should remain available at the site for some time. Liposomal gene transfer to more inner vessel layers with other catheters shows similar transfection efficiencies at higher doses; for example, less than 1% of cells were transfected by double balloon catheter with liposomal gene transfer. 31 Still better catheter systems and new liposome formulations individually optimized for the target tissue could improve on this. 32, 33 Transfer of plasmids carrying the gene encoding for the antimicrobial peptide pre-pro-cecropin A reduced neointima formation in vivo and inhibited proliferation. There are several reasons why these peptides might be suitable for the treatment of restenosis.
Cecropins were originally described as antibacterial peptides, but they can also act on mammalian cells. 12, 34 Cross-reactivity arises because mitochondria are endosymbionts of bacterial origin and therefore sensitive to antibacterial agents, in contrast to eukaryotic membranes. In mammalian fibroblast and erythrocyte cell lines, cecropins exhibit cytostatic or cytotoxic activity in a concentration-dependent manner.
14 Cecropins have antiproliferative effects on leukemia and lymphoma cell lines in vitro, and are generally less active against normal cells.
15, 16 We have shown an effect on smooth muscle cell proliferation in vitro within 7 days of transfection. In other work, introduction of the same pre-pro-cecropin A plasmid into human bladder carcinoma-derived cells reduces or abolishes tumorgenicity in vivo. 17 Administration of cecropins also results in increased survival of tumor-bearing nude mice. 16 Hybrid cecropin-mellitin constructs, which have much stronger antibacterial activity than cecropins alone, promote apoptotic cell death at low concentrations as a peptide derivate, whereas higher concentrations alter the plasma membrane integrity of macrophages. 35 We observed no increase in apoptotic cells in smooth muscle cells transfected with the cDNA of pre-pro-cecropin A. Both mature cecropin A and the pre-pro-form uncouple respiration and inhibit protein transport into mitochon- dria, resulting in a reduction in cell division through depletion in cellular energy. 36 The mature and immature forms of cecropin A have different actions on cells. Mature cecropin A is adsorbed to negatively charged cell membranes, leading to ␣-helical conformation of the basic N-terminal region, aggregation and cytotoxic effects through membrane pore formation. [37] [38] [39] In contrast, the immature (pre-pro-) form does not exhibit such toxicity, and its use results in a mainly cytostatic rather than cytotoxic effect.
14 This tied in with our aim to select a form of the gene for an insect antibiotic where the resultant cytostatic effects would inhibit proliferation without excessive toxicity. The prepro-cecropin A gene rather than the cDNA encoding for the mature peptide was delivered because purely cytotoxic strategies using suicide genes lead to inflammation and adverse effects on restenosis. We elected to deliver the gene and not the protein itself to ensure that only the less toxic immature form would be synthesized within targeted cells.
Despite successful transfection of relatively few vascular cells, a significant reduction in neointimal hyperplasia was observed with the pre-pro-cecropin A gene. This suggests a bystander effect, where the cecropin A peptide is secreted from transfected cells and affects growth of nontransfected neighboring cells, an effect also seen in our in vitro studies.
The combination of targeted gene therapy with improved vectors and appropriate local catheter-based delivery devices should optimize safety and maximize efficacy for the treatment of restenosis. This study demonstrates the feasibility and efficiency of the needle injec- 
Figure 6 PCR analysis of blood samples following plasmid application. No contamination with control plasmid of blood from locally treated pigs was detected by PCR (lanes 1-4). In the same DNA preparations, a 398 bp DNA fragment corresponding to the GAPDH sequence could be amplified (lanes 5-8). Following systemic administration of 30 g plasmid in a control pig, contaminating plasmid, a PCR product of 647 bp corresponding to the ␤-galctosidase gene, could be detected in blood at 5, 10, 15 and 30 min (lanes 9-12). Defined amounts of control plasmid added to blood samples in vitro were detected by PCR in the range of 10 −4 to 10 −6 fmol (lanes 13-15) but not 10 −7 fmol (lane 16). In the same samples, the 398 bp DNA fragment corresponding to the GAPDH sequence was consistently seen after amplification (lanes 17-20). M, 100 bp ladder.
tion catheter for therapeutic gene therapy. Cecropins may be potentially useful new therapeutic genes for the reduction of cell proliferation in arterial injury, particularly with their potential for a relevant bystander effect. The study suggests that the needle injection catheter in combination with the gene for pre-pro-cecropin A may be considered for clinical use.
Materials and methods

Plasmid vectors
For in vivo experiments, pre-pro-cecropin A cDNA from Hyalophora cecropia (GeneBank Acc. No. X06672) was amplified from the plasmid pCecrA 12 by PCR using the primer pair CA-L (5Ј-TATGACGTC-TCGTTAGAACG CGGCT-3Ј) and CA-R (5Ј-GGCAGATCT-TAAATGTAT-CATGCAAT-3Ј) carrying AatII and BglII restriction sites in the 5Ј extensions (bold nucleotides). The amplified fragment was prepared for cloning by digestion with AatII and BglII. The plasmid p125gal was opened by digestion with AatII and BamHI and the ␤-galactosidase gene was excised. The resulting 5 kb vector-containing fragment was ligated to the compatible pre-pro-cecropin A cDNA fragment, creating the plasmid p125.CecrA ( Figure 11) . The plasmid contains a neomycin resistance gene as part of the retroviral vector sequence. The pBAG plasmid containing the gene encoding for bacterial ␤-galactosidase was used for control experiments. 40 For in vitro experiments, pre-pro-cecropin A cDNA was amplified from p125.CecrA by PCR using the primer pair CA-L3 (5Ј-TCGCCCGGGGATCCTCTAGAAAG-3Ј) and CA-R3 (5Ј-ATGTATCATGCAATTCTTTTAACCCTTAG CA-3Ј), cloned into the TA cloning vector pCR2.1 (Invitrogen, Leek, The Netherlands) and subcloned into the pTRACER-SV40 vector (Invitrogen), which in addition to the cloned gene contains the gene for green fluorescent protein (GFP) fused with the Zeocin (Invitrogen) resistance marker.
In vitro studies
Primary smooth muscle cells were cultured as follows. Endothelial cells were removed from freshly explanted porcine aorta by trypsination. Small pieces of tissue were placed into culture flasks for outgrowth of smooth mus- cle cells. Cells were seeded into six-well plates after the second passage for transfection experiments and used at 80-90% confluency. The absence of endothelial cells was documented through the lack of positive staining after immunocytochemistry using an antibody against von Willebrand factor (Boehringer Mannheim, Mannheim, Germany). Cells were transfected using 3 g pTRACERplasmid complexed with 12 l LipofectAMINE (Gibco BRL Life Technologies, Eggenstein, Germany). Four hours later, the transfection mix was removed and smooth muscle cells were incubated in growth medium for 48 h, after which transfection efficiency was ascertained by fluorescence microscopy for expressed GFP. Fluorescence microscopy was also used 6 days after splitting to identify daughter cells, suggesting ongoing proliferation, and any apoptotic cells were identified by nuclear staining with 1 g/ml 4Ј,6-diamidino-2-phenylindole (DAPI; Sigma, Munich, Germany) in PBS and photographed using a Zeiss fluorescence microscope with filter 15 (Zeiss, Oberkochen, Germany). Cells were split 1:3 and placed into six-well plates. Certain wells were treated for 72 h with 500 g/ml Zeocin to select for transfected cells. Cells were harvested at various timepoints after passaging, and cell numbers and proliferation rates were determined for both Zeocin-treated and untreated cells with a particle counter (CASY 1, Schärfe System, Reutlingen, Germany). All measurements were undertaken in triplicate wells.
Porcine model
All animal procedures were approved by the Animal Care and Use Review Committee of Ludwig-Maximilians University and followed Bavarian State guidelines. Study animals were normal domestic pigs (average weight 22 kg at initial procedure; n = 27), fed a standard chow diet. Premedication was with an intramuscular injection of ketamine (500-1000 mg; Parke-Davis, Berlin, Germany), midazolam (10 mg; Hoffman-La Roche, GrenzachWyhlen, Germany) and atropine (1 mg; Braun, Melsungen, Germany). Sodium thiopental (125 mg; Byk Gulden, Konstanz, Germany) was injected through an ear vein and pigs were orotracheally intubated and mechanically ventilated. Anesthesia was maintained by ventilation with a nitrous oxide and oxygen mixture combined with 1.5-2% isoflurane (Lilly, Giessen, Germany).
Cutdowns to the right and left femoral arteries were performed using a sterile technique. Care was taken not to damage too much of the adventitia or perivascular tissue in either a proximal or distal direction. Vessels were measured and a balloon catheter (Baxter, Irvine, CA, USA or Boston Scientific Mansfield, Watertown, MA, USA) intended to be 1.3 times the size of the external vessel when inflated was selected. On both sides, sutures were used to sling the vessel and temporarily halt blood flow while the balloon was inserted through a longitudinal opening and passed proximally to 1 cm beyond the proximal sling. The balloon was inflated to 10 atmospheres for 1 min and then deflated and passed 2 cm further into the artery and reinflated to the same pressure for 1 min.
After deflation and withdrawal of the balloon, one artery was randomly designated as the side for gene therapy, the other as a control. Therapeutic or control genes (30 g DNA mixed with 120 g LipofectAMINE made up to a total of 2 ml with serum-free medium) were deposited in each experimental segment using a needle injection catheter (Bavaria Medizin Technologie, Oberpfaffenhofen, Germany). 22 The local drug delivery catheter was passed into the artery to a position 2 cm beyond the proximal sling. The 5F polyethylene catheter housed six 31 G curved needles in its shaft (Figure 4a) . When in position, the fine needles were extended so as to pierce the arterial wall for delivery into perivascular tissue. After delivery into the distal site, needles were retracted, the catheter was moved further to the second injured segment, needles were extended again and delivery performed in this location. Needles were returned to the housing and the needle injection catheter was removed. The artery was sutured with two stitches of prolene 4.0. Control vessels were merely injured with the same balloon, treated with the control gene or injured without injection and then sutured. Wounds on both sides were closed with intramuscular and subcutaneous vicryl 3.0 followed by silk to the skin.
Animals treated with the therapeutic and control genes were killed at time-points of 8 days or 21 days; six animals at each time-point. In addition, further animals with arteries treated with the control gene or undergoing injury without injection were killed at 8, 14 and 21 days (two, two and six animals per group, respectively). Animals were killed using the same anesthetic protocol, including orotracheal intubation and mechanical ventilation. Control vessels were removed before the gene therapy treated artery using RNase-free instruments. Blood samples and uninjured carotid arteries, skeletal muscle adjacent to the treated vessel and organs (liver, lung, spleen, heart, small intestine and kidney) were obtained for analysis of plasmid retention at 8 days. In two further pigs, detection of blood plasmid was carried out on samples taken 5, 10, 20 and 30 min after 30 g DNA was administered either systemically or locally as above. Uninjured normal iliac arteries were removed from untreated pigs as independent controls (n = 3). Pigs were killed with potassium chloride under general anesthetic. Tissue preparation Serial specimens of tissue from arteries (iliac and carotid) and organs were divided and rapidly immersed in icecold 4% paraformaldehyde (Fisher Scientific, Fair Lawn, NJ, USA) or snap-frozen in liquid nitrogen. Paraformaldehyde-fixed tissue was transferred after 2 h into 30% sucrose/PBS mixture and stored overnight at 4°C. After embedding in OCT compound (Miles Scientific, Elkhart, IN, USA), tissues were snap-frozen in liquid nitrogen, stored at −70°C and later sectioned on a cryostat (Miles). Sections were placed on electrically charged glass slides (Fisher) and kept at −70°C. obtained from Boehringer Mannheim were used for size calculation. The molecular weight marker VI is pBR328 cleaved with BglI/HinfI and molecular weight marker VIII is a mixture of pUC21 cleaved with HpaII and, for the lower molecular weight range, pUC21 with HindIII/DraI. Serum was separated from whole blood by centrifugation. To recover plasmid DNA from serum, 1 g genomic DNA from untreated pigs was added and extracted by the phenol-chloroform-isoamylalcohol method. Control experiments with genomic DNA supplemented with plasmid DNA added in variable concentrations were performed. The quality of the DNA was tested by PCR with specific primers for the GAPDH gene (L1: CGTCTTCAC-CACCATGGAAGAAGGC and R2: AAGGCCATGC CAGTGAGCTTCCC, 398 bp). The ␤-galactosidase gene was detected by PCR with the specific primers L2: TCTA-GAGGATCCGGTACTCGAG and R2: GACCGTAAT GGGATAGGTTAC (647 bp). The PCR was performed as described above.
Analysis of expression of plasmid-containing reporter gene ␤-Galactosidase expression was evaluated in frozen 7 m tissue sections fixed in 4% paraformaldehyde using a previously defined protocol. 40 The time-course of expression was investigated in pigs locally transfected with the ␤-galactosidase gene and killed after 8, 14 or 21 days. Pigs receiving the gene for pre-pro-cecropin A had two additional segments at the contralateral side transfected with the control gene. Five sections, at least 1 mm apart from each other, from each injury site were analyzed in triplicate to ascertain transfection efficiency in each segment. All cells in each arterial wall layer were counted. Thus, at the 8 day time-point, a total of 360 fields was examined from 12 arterial segments from the six control gene-transfected animals.
pBAG-transfected primary human smooth muscle cells were stained for ␤-galactosidase activity as positive controls for the procedure. Blue cells at histological analysis indicated successful transfection and expression, and all stained and non-stained cells in the tissue sections were counted.
Analysis of mRNA from plasmid-containing therapeutic gene Reverse transcription PCR analyses were performed to detect specific mRNA from the transferred genes. Snapfrozen tissue was homogenized in liquid nitrogen and RNA was prepared with RNAzol B reagent (CINNA/MRC, Cincinnati, OH, USA). A total of 1-5 g RNA was reverse transcribed employing the T-Primed First-Strand cDNA synthesis Ready To Go-Kit (Pharmacia, Freiburg, Germany). A PCR of 35 cycles was performed with 5 pmol of each specific primer pair for the transferred genes using 50 ng reverse transcribed total RNA as template or untranscribed RNA to detect DNA contamination. The quality of transcribed RNA was shown by amplification of the 5Ј-end of the ␤-actin gene transcript (BACTl L: 5Ј-GGCTGTATTCCCCTCCATCG TGG-3Ј/BACTl R: 5Ј-GGCTGTATTCCCCTCCATCGTG G-3Ј; 187 bp fragment). For all transferred plasmids, three independent primer pairs were utilized for detection of exogenous gene expression, two pairs to amplify the therapeutic (p125 L/CecrA R1: see section above 'Detection of transferred plasmid DNA' and CecrA L2: 5Ј-GACGGCTCTAGCAATGGTCAATGC-3Ј/Cecr R3: 5Ј-ATGTATCATGCAATTCTTTTAACCCTTAGCA-3Ј, 172 bp) or control gene (␤-Gal L1: 5Ј-ATCGCGTCACAC-TACGTCTGAACGTC-3Ј/␤-Gal R1: 5Ј-AAACCGCCAA-GACTGTTACCCATCG-3Ј, 788 bp and ␤-Gal L1/pBAGGal2R: 5Ј-TTCATCCACCACATACAGGC-3Ј, 377bp), one pair for GFP (L2: 5Ј-GCTGACCCTGAAGTTCATCTG CAGC-3Ј/R1:5Ј-TTACTTGTACAGCTCGTCCATGCCG AG-3Ј, 595 bp), one pair for the neomycin resistance gene (Neo L1/Neo R2; see above). All tests were performed at least twice. Amplified DNA fragments were analyzed by electrophoresis on agarose gels. The molecular weight marker VI (pBR328 cleaved with BglI and HinfI) and VIII (a mixture of pUC21 cleaved with HpaII and for the lower molecular weight range pUC21 with HindIII/DraI) were used for calculation of fragment sizes. Specificity of amplified fragments was verified using restriction pattern analysis.
Immunohistochemistry
At the 8 day time-point, frozen 7 m tissue sections from the treated artery were compared with sections from the contralateral control-transfected artery. Proliferating cells were stained using a Ki67 antibody at 1:5 dilution (clone MIB-1; Dianova, Hamburg, Germany). All staining procedures were conducted at room temperature except the incubation of the primary antibody, which was performed at 37°C. After fixation with acetone and quenching of endogenous peroxidases with 1% H 2 O 2 (in phosphatebuffered saline solution), sections were blocked with 1.5% normal horse serum, incubated with a primary antibody, washed extensively, and incubated with a biotinylated secondary antibody and coupled avidin-peroxidase complex (Vectastain Elite ABC Kit; Vector Laboratories, Burlingame, CA, USA). Sections were stained with AEC (3-amino-9-ethyl carbazole) as a peroxidase substrate (Vector Laboratories) and counterstained with hematoxylin. Stained cells were counted and related to the area of tissue per section.
Morphometric analysis
Morphometry data were obtained by analyzing five sections, at least 1 mm apart from each other from each injury site in triplicate, to ascertain mean neointimal areas in each segment. Thus, 360 fields were examined from 12 therapeutic gene-transfected segments and similarly from the 12 control gene-transfected arteries from six experimental animals. Sections were counterstained with hematoxylin and eosin, or elastic-trichrome, and examined by light microscopy at various magnifications (4 × to 500 ×). Computer-assisted area measurements were performed at 4 × magnification with a microscope linked to a chargecoupled device (CCD) camera (Nikon 104, Dü sseldorf, Germany) connected to a Macintosh computer. Digitized pictures were analyzed with Image, a standard software program for area calculation (National Institutes of Health, Bethesda, MD, USA, public domain). Neointimal areas were compared in arteries treated with therapeutic and control genes.
Statistical analysis
Results are expressed as mean ± s.e.m. for each artery. Comparisons use a one-way analysis of variance with Scheffes F test. Statistical significance was set at P Ͻ 0.05.
